WallStreetZenWallStreetZen

NASDAQ: GCTK
Glucotrack Inc Stock

Overview
EarningsRevenueDividendOwnership
$0.17+0.00 (+0%)
Updated Apr 30, 2025
GCTK Price
$0.17
Fair Value Price
$0.02
Market Cap
$4.43M
52 Week Low
$0.13
52 Week High
$79.00
P/E
0x
P/B
-0.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.60M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.46
Operating Cash Flow
-$12M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

GCTK Overview

GlucoTrack, Inc., a medical device company, develops non-invasive glucose monitoring devices for people suffering from diabetes and pre-diabetics. Known as Integrity Applications, Inc. until 2021/11, GlucoTrack was founded in 2001 and is based in Or Yehuda, Israel.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GCTK's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
B
GCTK
RankedUnranked of 42

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Pro Dex (PDEX)
$65.68B
Infusystem Holdings (INFU)
$4.72B
Becton Dickinson & Co (BDX)
$207.09B
View Top Medical Stocks

Be the first to know about important GCTK news, forecast changes, insider trades & much more!

GCTK News

Overview

Due Diligence Score

–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GCTK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GCTK ($0.17) is overvalued by 927.7% relative to our estimate of its Fair Value price of $0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GCTK ($0.17) is not significantly undervalued (927.7%) relative to our estimate of its Fair Value price of $0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GCTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GCTK due diligence checks available for Premium users.

Valuation

GCTK fair value

Fair Value of GCTK stock based on Discounted Cash Flow (DCF)

Price
$0.17
Fair Value
$0.02
Overvalued by
909.88%
GCTK ($0.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GCTK ($0.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GCTK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GCTK price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
40.62x
Market
29.18x

GCTK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-0.34x
Industry
3.73x

GCTK's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.1M
Profit Margin
0%
GCTK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$5.9M
Liabilities
$18.9M
Debt to equity
-1.46
GCTK's short-term assets ($5.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GCTK's long-term liabilities ($17.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GCTK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GCTK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.5M
Investing
$0.0
Financing
$8.8M
GCTK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GCTK vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GCTK–$4.43M+1.17%-0.00x-0.34x
LUCY–$4.73M+2.12%-0.37x0.52x
STSSF$305.44k+12.20%-0.00x0.15x
MHUA–$8.77M-4.18%0.69x0.06x
POAI–$9.82M+2.80%-0.47x-48.49x
View Top Medical Stocks

Glucotrack Stock FAQ

What is Glucotrack's quote symbol?

(NASDAQ: GCTK) Glucotrack trades on the NASDAQ under the ticker symbol GCTK. Glucotrack stock quotes can also be displayed as NASDAQ: GCTK.

If you're new to stock investing, here's how to buy Glucotrack stock.

What is the 52 week high and low for Glucotrack (NASDAQ: GCTK)?

(NASDAQ: GCTK) Glucotrack's 52-week high was $79.00, and its 52-week low was $0.13. It is currently -99.78% from its 52-week high and 32.06% from its 52-week low.

How much is Glucotrack stock worth today?

(NASDAQ: GCTK) Glucotrack currently has 25,585,853 outstanding shares. With Glucotrack stock trading at $0.17 per share, the total value of Glucotrack stock (market capitalization) is $4.43M.

Glucotrack stock was originally listed at a price of $8,125.00 in Apr 25, 2013. If you had invested in Glucotrack stock at $8,125.00, your return over the last 12 years would have been -100%, for an annualized return of -59.2% (not including any dividends or dividend reinvestments).

How much is Glucotrack's stock price per share?

(NASDAQ: GCTK) Glucotrack stock price per share is $0.17 today (as of Apr 30, 2025).

What is Glucotrack's Market Cap?

(NASDAQ: GCTK) Glucotrack's market cap is $4.43M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Glucotrack's market cap is calculated by multiplying GCTK's current stock price of $0.17 by GCTK's total outstanding shares of 25,585,853.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.